[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571942":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":22,"responsibleParty":43,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"CHRISTUS Health","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Droperidol injection","2.5 mg",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Aaron K Bartoe, DO, MS","CONTACT","(863) 532-8408","aaronkbartoe@gmail.com",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Peter Richman, MD, MBA","prichmanmdmba@gmail.com",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"CHRISTUS Spohn Hospital Corpus Christi-Shoreline","RECRUITING","Corpus Christi","Texas","78405","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-97.39638,27.80058,{"lat":35,"lon":34},[38,41],{"name":39,"role":16,"phone":40,"phoneExt":7,"email":18},"Aaron Bartoe, DO, MS","(817) 999-8167",{"name":42,"role":16,"phone":40,"phoneExt":7,"email":21},"Peter Richman, MD, MS",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Aaron Bartoe","Principal Investigator","100571942","droperidol-and-qtc-interval-changes-in-ed-patients-100571942",false,"NCT06726811","Droperidol and QTc Interval Changes in ED Patients","Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients","Inclusion Criteria:\n\n* ED patients ages 18 years or older in a cardiovascular-monitored bed who have both an ECG and a 2.5 mg dose of IV droperidol ordered by their treating physician will be eligible for inclusion.\n\nExclusion Criteria:\n\n* Refusal to provide consent.\n* Administration of droperidol before the first ECG is performed.\n* Inability to complete the consent form and questionnaire due to clinical instability, severe pain, or disorientation as determined by a study physician.","ALL","18 Years",{"count":57,"type":58},500,"ESTIMATED","OBSERVATIONAL","Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval.\n\nHypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.",[62,63],"Emergency Department Patient","QTc Intervals Changes",[65,66,67],"Droperidol","QTc Interval Changes","Emergency Department Patients","2024-12-12",{"date":70,"type":71},"2024-12-17","ACTUAL",{"date":73,"type":71},"2024-10-17",{"date":75,"type":58},"2026-09-30",{"name":5,"class":6},1]